Skip to content

Viridian Therapeutics, Inc. VRDN Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

PVL
Palvella TherapeuticsPVLA
-$15.76M-92.3%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$53.17M+46.4%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$159.56M-254%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$722.22M-297,309%
Arrowhead Research logo
Arrowhead ResearchARWR
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%
Enterprise value$1.77B+85.0%
P/S26.9×-3,445×

Profitability

See full
Gross margin36.3%
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Viridian Therapeutics, Inc. (VRDN) reported comprehensive income (loss), net of tax, attributable to parent of -$105.91M in Q1 2026.
How has Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 22.2% year-over-year, from -$86.66M to -$105.91M.
What is the long-term trend for Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 44.0% compound annual growth rate (CAGR), from -$79.56M to -$342.14M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a comprehensive view of the company's financial performance by including all recognized revenues, expenses, gains, and losses. Investors use this to assess the total impact of all financial activities on the company's net worth beyond standard operating results.